摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(Octane-1-sulfonyl)-3-[4-(2-piperidin-yl-ethoxy)-phenyl]-propionic acid hydroxyamide | 212766-41-1

中文名称
——
中文别名
——
英文名称
2-(Octane-1-sulfonyl)-3-[4-(2-piperidin-yl-ethoxy)-phenyl]-propionic acid hydroxyamide
英文别名
2-(octane-1-sulfonyl)-3-[4-(2-piperidin-4-yl-ethoxy)phenyl]propionic acid hydroxamide;N-hydroxy-2-octylsulfonyl-3-[4-(2-piperidin-1-ylethoxy)phenyl]propanamide
2-(Octane-1-sulfonyl)-3-[4-(2-piperidin-yl-ethoxy)-phenyl]-propionic acid hydroxyamide化学式
CAS
212766-41-1
化学式
C24H40N2O5S
mdl
——
分子量
468.658
InChiKey
PRLGEFXGCXSHFM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    32
  • 可旋转键数:
    15
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    104
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2-(Octane-1-sulfonyl)-3-[4-(2-piperidin-yl-ethoxy)-phenyl]-propionic acid 以89%的产率得到2-(Octane-1-sulfonyl)-3-[4-(2-piperidin-yl-ethoxy)-phenyl]-propionic acid hydroxyamide
    参考文献:
    名称:
    N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS
    摘要:
    公开号:
    EP0970046B1
点击查看最新优质反应信息

文献信息

  • [EN] N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] ALKYLE, ARYLE OU HETEROARYLAMIDES N-HYDROXY-2-(ALKYL, ARYL OU HETEROARYL SULFANYL, SULFINYL OU SULFONYL)-3-SUBSTITUES EN TANT QU'INHIBITEURS DE LA METALLOPROTEINASE MATRICIELLE
    申请人:AMERICAN CYANAMID COMPANY
    公开号:WO1999042436A1
    公开(公告)日:1999-08-26
    (EN) Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-$g(a) converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-$g(a) from membrane bound TNF-$g(a) precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-$g(a) converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having formula (I), wherein R2 and R3 form a heterocyclic ring and A is S, S(O), or S(O)2 and R1 and R4 are defined herein.(FR) L'invention concerne les métalloprotéinases matricielles (MMP) qui sont un groupe d'enzymes impliquées dans la destruction pathologique d'un tissu conjonctif et d'une membrane basale. Ces endopeptidases contenant du zinc sont formée de différents sous-ensembles d'enzymes comprenant des collagénases, des stomélysines et des gélatinases. L'enzyme de conversion TNF-$g(a) (TACE), une cytokine pro-inflammatoire, catalyse la formation de TNF-$g(a) à partir d'une membrane liée à la protéine précurseur TNF-$g(a). On pense que de petits inhibiteurs de molécules de MMP et TACE sont en mesure de traiter un certain nombre de pathologies. L'invention concerne en outre des inhibiteurs non peptidiques à faible poids moléculaire de métalloprotéinases matricielles (MMP) et d'une enzyme de conversion TNF-$g(a) (TACE) pour le traitement de l'arthrite, de métastases tumorales, d'ulcération tissulaire, de subérification d'une blessure anormale, de parodontopathie, de maladies osseuses, du diabète (résistance insulinique) de l'infection par VIH de formule (I), dans laquelle R2 et R3 désignent un noyau hétérocyclique et A désigne S, S(O) ou S(O)2 et R1 et R4 sont tels que définis.
    基质金属蛋白酶(MMPs)是一组酶,已被认为参与了结缔组织和基底膜的病理性破坏。这些含锌的内切酶包括几个亚组酶,包括胶原酶、基质金属蛋白酶和明胶酶。TNF-$g(a)转化酶(TACE)是一种促炎细胞因子,催化膜结合型TNF-$g(a)前体蛋白形成TNF-$g(a)。因此,MMPs和TACE的小分子抑制剂具有治疗多种疾病的潜力。本发明提供了低分子量、非肽类基质金属蛋白酶(MMPs)和TNF-$g(a)转化酶(TACE)的抑制剂,用于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周病、骨病、糖尿病(胰岛素抵抗)和HIV感染,其化学式为(I),其中R2和R3形成杂环环,A为S、S(O)或S(O)2,R1和R4如本文所定义。
  • [EN] N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] N-HYDROXY-2-(ALKYL,ARYL OU HETEROARYL SULFANYL, SULFINYL OU SULFONYL)-ALKYL, ARYL OU HETEROARYLAMIDES SUBSTITUES EN POSITION 3, UTILISES COMME INHIBITEURS DES METALLOPROTEINASE MATRICIELLE
    申请人:AMERICAN CYANAMID COMPANY
    公开号:WO1998038163A1
    公开(公告)日:1998-09-03
    (EN) Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-$g(a) converting enzymes (TACE), a pro-inflammatory cytokine, catalyze the formation of TNF-$g(a) from membrane-bound TNF-$g(a) precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-$g(a) converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection. The compounds of this invention are represented by formula (I), where R1, R2, R3 and R4 are described herein.(FR) Les métalloprotéinases matricielles (MMP) sont un groupe d'enzymes ayant été impliquées dans la destruction pathologique de la membrane basale et du tissu conjonctif. Ces endopeptidases contenant du zinc consistent en plusieurs sous-ensembles d'enzymes comprenant des collagénases, des stromélysines et des gélatinases. L'enzyme de conversion de TNF-$g(a) (TACE), une cytokine pro-inflammatoire, catalyse la formation de TNF-$g(a) à partir de la protéine précurseur de TNF-$g(a) liée à la membrane. On suppose que les inhibiteurs à petites molécules de MMP et TACE ont donc la capacité de traiter plusieurs états pathologiques. L'invention se rapporte à des inhibiteurs de non peptides, à faible poids moléculaire, des métalloprotéinases matricielles (MMP) et à l'enzyme de conversion TNF-$g(a) (TACE) pour le traitement de l'arthrite, de métastases tumorales, de l'ulcération de tissu, de cicatrisation anormale, de la parodontopathie, les maladies osseuses, de diabètes (résistance à l'insuline) et de l'infection au VIH. Les composés de l'invention sont représentés par la formule (I), R1, R2, R3 et R4 étant décrits.
    基质金属蛋白酶(MMP)是一组酶,已被认为参与了结缔组织和基底膜的病理性破坏。这些含锌的内切酶由几个亚组成,包括胶原酶、基质金属蛋白酶和明胶酶。TNF-$g(a)转化酶(TACE)是一种促炎细胞因子,可催化膜结合型TNF-$g(a)前体蛋白形成TNF-$g(a)。因此,MMP和TACE的小分子抑制剂有望治疗多种疾病。本发明提供了用于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周病、骨病、糖尿病(胰岛素抵抗)和HIV感染的基质金属蛋白酶(MMP)和TNF-$g(a)转化酶(TACE)的低分子量非肽抑制剂。本发明的化合物由公式(I)表示,其中R1、R2、R3和R4如本文所述。
  • N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    申请人:American Cyanamid Company
    公开号:US20020188120A1
    公开(公告)日:2002-12-12
    Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula 1 wherein R 2 and R 3 form a heterocyclic ring and A is S, S(O), or S(O)2, and R 1 and R 4 are defined herein.
    基质金属蛋白酶(MMPs)是一组酶,已被认为与结缔组织和基底膜的病理性破坏有关。这些含锌内切酶包括几个酶亚组,包括胶原酶、基质金属蛋白酶和明胶酶。TNF-α转化酶(TACE)是一种促炎细胞因子,催化膜结合的TNF-α前体蛋白形成TNF-α。因此,MMPs和TACE的小分子抑制剂有潜力用于治疗多种疾病状态。本发明提供了基质金属蛋白酶(MMPs)和TNF-α转化酶(TACE)的低分子量、非肽抑制剂,用于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周病、骨病、糖尿病(胰岛素抵抗)和HIV感染,其化学式为1,其中R2和R3形成杂环环,A为S、S(O)或S(O)2,R1和R4如本文所定义。
  • N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
    申请人:American Cyanamid Company
    公开号:US20020032186A1
    公开(公告)日:2002-03-14
    Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflmatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula 1 wherein R 2 and R 3 form a heterocyclic ring and A is S, S(O), or S(O) 2 , and R 1 and R 4 are defined herein.
    基质金属蛋白酶(MMPs)是一组酶,已被证明与结缔组织和基底膜的病理性破坏有关。这些含锌内切酶包括几个亚组酶,包括胶原酶、基质金属蛋白酶和明胶酶。TNF-α转化酶(TACE)是一种促炎细胞因子,它催化从膜结合的TNF-α前体蛋白形成TNF-α。因此,MMPs和TACE的小分子抑制剂有治疗多种疾病的潜力。本发明提供了低分子量、非肽类的基质金属蛋白酶(MMPs)和TNF-α转化酶(TACE)抑制剂,用于治疗关节炎、肿瘤转移、组织溃疡、异常愈合、牙周病、骨病、糖尿病(胰岛素抵抗)和HIV感染,其化学式为1,其中R2和R3形成杂环环,A为S、S(O)或S(O)2,R1和R4如本文所定义。
  • N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS
    申请人:American Cyanamid Company
    公开号:EP0973512A1
    公开(公告)日:2000-01-26
查看更多